Payment overview · 2025
General Payments
$1,505.05
65 reported records · 13 companies
Healthcare provider profile · identity verified
Glenn D Rosen, MD
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1629115340
Verified facts
What the public records show
CMS Open Payments records show Glenn D Rosen, MD received $1,505.05 in general payments during 2025 across 65 reported records.
Abbott Laboratories accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $354.69 | 23.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $311.74 | 20.7% | 23 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $143.10 | 9.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $114.14 | 7.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $112.73 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.65 | 7.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.65 | 6.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.96 | 6.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.12 | 3.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $49.19 | 3.3% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $33.05 | 2.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.57 | 1.4% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $13.46 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,406.05 | 64 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $354.69 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $170.82 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $151.25 | 5 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $143.10 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $112.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.96 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.96 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.81 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $78.96 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.58 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.34 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.06 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| DYSPORT Normalized: dysport |
Drug | Galderma Laboratories, L.P. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 188 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 39 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
171 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 617 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 123 |
| Omeprazole | Omeprazole | 368 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 333 | 81 |
| Gabapentin | Gabapentin | 327 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 317 | 85 |
| Simvastatin | Simvastatin | 308 | 75 |
| Metformin Hcl | Metformin Hcl | 288 | 71 |
| Losartan Potassium | Losartan Potassium | 258 | 71 |
| Alprazolam | Alprazolam | 239 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 57 |
| Furosemide | Furosemide | 192 | 49 |
| Jardiance | Empagliflozin | 188 | 39 |
| Ibuprofen | Ibuprofen | 183 | 59 |
| Lisinopril | Lisinopril | 176 | 41 |
| Trulicity | Dulaglutide | 171 | 25 |
| Meloxicam | Meloxicam | 146 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 33 |
| Eliquis | Apixaban | 143 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 44 |
| Prednisone | Prednisone | 135 | 71 |
| Ozempic | Semaglutide | 133 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 23 |
| Azithromycin | Azithromycin | 124 | 90 |
| Nifedipine Er | Nifedipine | 119 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 31 |
| Potassium Chloride | Potassium Chloride | 107 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 38 |
| Trazodone Hcl | Trazodone Hcl | 103 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 30 |
| Carvedilol | Carvedilol | 97 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 18 |
| Allopurinol | Allopurinol | 92 | 16 |
| Montelukast Sodium | Montelukast Sodium | 92 | 21 |
| Lidocaine | Lidocaine | 89 | 18 |
| Farxiga | Dapagliflozin Propanediol | 88 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 28 |
| Azelastine Hcl | Azelastine Hcl | 84 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 20 |
| Mupirocin | Mupirocin | 83 | 25 |
| Colchicine | Colchicine | 74 | 15 |
| Baclofen | Baclofen | 70 | 21 |
| Clonidine Hcl | Clonidine Hcl | 69 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 69 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 19 |
| Celecoxib | Celecoxib | 67 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Entresto | Sacubitril/Valsartan | 63 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 15 |
| Clonazepam | Clonazepam | 61 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 12 |
| Nystatin | Nystatin | 60 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 12 |
| Famotidine | Famotidine | 59 | 15 |
| Linzess | Linaclotide | 55 | 11 |
| Ketoconazole | Ketoconazole | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 38 |
| Diazepam | Diazepam | 52 | 11 |
| Atenolol | Atenolol | 51 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 11 |
| Tramadol Hcl | Tramadol Hcl | 50 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 11 |
| Myrbetriq | Mirabegron | 48 | 12 |
| Temazepam | Temazepam | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 14 |
| Valsartan | Valsartan | 45 | 14 |
| Lorazepam | Lorazepam | 44 | 16 |
| Amoxicillin | Amoxicillin | 43 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 25 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 40 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Risperidone | Risperidone | 37 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Naproxen | Naproxen | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Veozah | Fezolinetant | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Daliresp | Roflumilast | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.05 · 65 records | Abbott Laboratories | BREZTRI, CREON, DAXXIFY, DYSPORT, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LINZESS, MOUNJARO, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Xeomin, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error